

# Philadelphia Department of Public Health Healthcare-Associated Infections/Antimicrobial Resistance Program

## Carbapenem-resistant *Enterobacteriaceae* (CRE)

Quarterly Report | Quarter 1, 2019



CRE Case Counts, by Status		
Confirmed*	Probable	No Case
78	0	4


Carbapenemase-Producing CRE (CP-CRE)						33
Mechanisms for CP-CRE	KPC	NDM	IMP	OXA-48	VIM	Pending/Not Tested
	27	4	0	0	0	

Patient Residence	
Philadelphia	Out of Jurisdiction
55 (70.5)	23 (29.5)

CRE Counts <sup>†</sup> , by Genus Species and Mechanism						
Genus Species	n (%)	KPC	NDM	IMP	OXA-48	VIM
<i>Klebsiella pneumoniae</i>	30 (38.5)	19	.	.	.	.
<i>Enterobacter cloacae</i>	13 (16.7)	2	.	.	.	.
<i>Escherichia coli</i>	11 (14.1)	3	2	.	.	.
<i>Proteus mirabilis</i>	6 (7.8)	.	.	.	.	.
<i>Morganella morganii</i>	4 (5.1)	.	.	.	.	.
<i>Providencia</i> spp.	4 (5.1)	.	.	.	.	.
<i>Citrobacter</i> spp.	3 (3.9)	2	.	.	.	.
<i>Serratia marcescens</i>	3 (3.9)	1	.	.	.	.
Other <i>Enterobacteriaceae</i>	4 (5.2)	.	2	.	.	.

<sup>†</sup>not all isolates sent for mechanism testing


Specimen Sources of CRE Cases (n=88\*)



\*One case can have more than one specimen source

Epidemiological Characteristics of CRE Cases			
Characteristics	Yes	No	Unknown
LTCF Resident	22 (28.2)	6 (7.7)	50 (64.1)
Healthcare Abroad	0 (0.0)	2 (2.6)	76 (97.4)
Fatal	4 (5.1)	18 (23.1)	56 (71.8)
Scoping Procedure, in Past Year	7 (9.0)	6 (7.7)	65 (83.3)
Surgery (non-scoping), in Past Year	5 (6.4)	0 (0.0)	73 (93.6)
Invasive Device(s)	28 (35.9)	14 (18.0)	36 (46.1)
History of CRE	10 (12.8)	20 (25.6)	48 (61.5)

CRE Cases, by Carbapenemase-Producing (CP) Status, October 2018 - March 2019



\*unless otherwise specified, all data represent confirmed cases.